acid reflux and tirzepatide Zepbound Heartburn: Causes, Relief & GLP-1 Alternatives Mounjaro and Acid Reflux: Causes

Contact Invita Wellness today, and give your mitochondria a boost with a glutathione IV cocktail

doi: 10.1038/cdd.2014.53

Cardiovascular Evidence# LEADER Trial (Liraglutide)# The LEADER trial (Marso et al., NEJM 2016) enrolled 9,340 patients with T2D and high CV risk, followed for median 3.8 years: 3-point MACE: HR 0.87 (95% CI 0.78-0.97, p=0.01) -- 13% reduction Cardiovascular death: HR 0.78 (22% reduction) All-cause mortality: HR 0.85 (15% reduction) Liraglutide was the first GLP-1 agonist to demonstrate cardiovascular benefit, and LEADER remains a landmark trial in the class

semaglutide: side effects Liraglutide and semaglutide share many side effects, both rare and serious